Loading
A phase 2 trial of Vebreltinib in metastatic cancer and thyroid cancer, run by Apollomics Inc., now recruiting.
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is a phase 2 interventional study registered as NCT03175224 by Apollomics Inc., with 497 participants planned, started 2017-09-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: APL-101 Oral Capsules. Conditions listed: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/